Name: July 2025 OLU provider newsletter **Subject:** Aetna monthly OfficeLink Updates, July 2025 -- policy changes and updates

Preheader: Learn about important policy updates, material changes and amendments

♥aetna[®]

Trouble viewing this email message? Read it online.

July 2025

We regularly review and adjust our clinical, payment

edits on our provider portal on Availity®.* Just go to Payer Space > Resources > Expanded Claim Edits.

As of June 18, 2025, we require precertification for the

denosumab-dssb (J3490, J3590, C9399)

Stoboclo® (denosumab-bmwo, J3490, J3590,

- Ospomyv[™] (denosumab-dssb, J3490, J3590,
- C9399) Xbryk[™] (denosumab-dssb, J3490, J3590, C9399)
- following:
 - C9399)

 Pyzchiva® (ustekinumab-ttwe, J3490, J3590, C9399)

- C9399) (precertification includes the site of care (SOC))
- C9399) Yesintek™ (ustekinumab-kfce, J3490, J3590, C9399)

Imuldosa® (ustekinumab-srlf, J3490, J3590, C9399)

 Surgical management of Temporomandibular Joint (TMJ) (D7830, D7871)

D7949, D7950, D7955, D7995, D7996)

- Effective July 15, 2025, we'll require precertification for the following: Encelto[™] (revakinagene taroretcel-lwey, J3490,
- through our provider portal on Availity.* Doing so is fast, secure and simple.

You can also use your practice's Electronic Medical

Record (EMR) system if it's set up for electronic

precertification requests. Use our "Search by CPT® code" function on our Precertification Lists page to find out if the code requires precertification.**

**CPT® is a registered trademark of the American Medical Association. 2024 All rights reserved. Note to Maine and Vermont providers: For commercial plans, your effective date for routine changes described

in this article will be the statutory date of January 1, April 1, July 1 or October 1, whichever date follows the effective date(s) referred to in this article. Changes required by state or federal law, or pursuant to revisions of Current Procedural Terminology (CPT®) codes published by the American Medical Association, may be effective outside

medications administered in an outpatient hospital site. These changes will affect only those patients who are new to therapy after October 1. Certain oncology drugs will have an initial approval of 90 days when a place of service is outpatient hospital.

The affected oncology drugs are the following Immune

You can access the Site of Care for Specialty Drug Administration policy and the medications to which this policy applies on our **<u>Drug infusion/injection site of care</u>**

policy page.

- You can always find this information on our provider portal on Availity.*
 - **Availity portal**

respective owners. Help/contact us: If you have any questions, please contact us.

Want to stop receiving email messages like these? **Unsubscribe** at any time.

 Avtozma® (tocilizumab-anoh, J3490, J3590, Stegeyma® (ustekinumab-stba, J3490, J3590,

 Electric scooters (E1230) Orthognathic surgery (D7296, D7940, D7941,

D7943, D7944, D7945, D7946, D7947, D7948,

- Hyperbaric oxygen therapy (HBOT) (99183, G0277)
- Submit precertification requests at least two weeks in advance and include the actual date of service in the

request. To save time, request precertification online

If you need precertification for a specialty drug for a

On October 1, 2025, we're updating our initial prior authorization approval timeline for certain oncology

begin on October 1

Affected drugs

Checkpoint Inhibitors:

Bavencio

 Jemperli Keytruda Libtayo Loqtorzi Opdivo

Opdivo Qvantig

Tecentriq Hybreza

 Opdualag Tecentriq

Imfinzi

- You can also use our Code Edit Lookup tools on Availity®. Just go to Payer Space > Applications > Code Edit Lookup Tools. Keep your Aetna provider ID number handy to access

*Availity® is available only to providers in the U.S. and its territories.

Aetna® is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).

Privacy Statement | Terms of Use | Privacy Information

This month's reminders

and coding policies. Review our policies and claim

Changes to our National Precertification List (NPL) These changes apply to our commercial and Medicare members.

following:

 Osenvelt® (denosumab-bmwo, J3490, J3590, C9399)

C9399)

As of June 23, 2025, we require precertification for the

 Selarsdi™ (ustekinumab-aekn, J3490, J3590, ustekinumab-aekn (J3490, J3590, C9399) ustekinumab-ttwe (J3490, J3590, C9399)

Effective July 1, 2025, we'll no longer require

precertification for the following:

- For Medicare plans only, we'll no longer require precertification for the following:
- Submitting precertification requests

J3590, C9399)

territories.

commercial or Medicare member, submit your request through Novologix®, also available on Availity. *Availity® is available only to providers in the U.S. and its

the statutory dates outlined above. Site-of-care prior authorization timeline changes for certain oncology drugs

 Tevimbra Unloxcyt Yervoy Zynyz Note that this change will affect only new approvals, not existing ones. **More information**

them.

rights reserved.

**CPT® is a registered trademark of the American Medical Association. 2024 All

All registered company names, products and services are the property of their

We are located at 151 Farmington Avenue, Hartford, CT 06156. ©2025 Aetna Inc. 5384116-01-01

Name: July 2025 OLU provider newsletter

Aetna monthly OfficeLink

Updates, July 2025 -- policy

Preheader: and amendments

changes and updates

updates, material changes

♥aetna

We regularly review and

reminders

adjust our clinical, payment

and coding policies. Review

our policies and claim edits

on our provider portal on

Availity®.* Just go to Payer

Space > Resources >

Expanded Claim Edits.

Changes to our National

and Medicare members.

C9399)

As of June 18, 2025, we require precertification for the following:

Precertification List (NPL)

These changes apply to our commercial

denosumab-dssb (J3490, J3590,

Osenvelt® (denosumab-bmwo,

Stoboclo® (denosumab-bmwo,

Ospomyv[™] (denosumab-dssb,

Xbryk[™] (denosumab-dssb, J3490,

J3490, J3590, C9399)

J3490, J3590, C9399)

J3490, J3590, C9399)

As of June 23, 2025, we require precertification for the following:

J3490, J3590, C9399)

C9399)

Selarsdi™ (ustekinumab-aekn,

ustekinumab-aekn (J3490, J3590,

ustekinumab-ttwe (J3490, J3590,

Pyzchiva® (ustekinumab-ttwe,

Avtozma® (tocilizumab-anoh,

(precertification includes the site of

Stegeyma® (ustekinumab-stba,

Yesintek™ (ustekinumab-kfce,

Imuldosa® (ustekinumab-srlf,

Effective July 1, 2025, we'll no longer require precertification for the following:

J3490, J3590, C9399)

Electric scooters (E1230)

Surgical management of

(D7830, D7871)

(99183, G0277)

D7996)

Orthognathic surgery (D7296,

D7940, D7941, D7943, D7944, D7945, D7946, D7947, D7948, D7949, D7950, D7955, D7995,

Temporomandibular Joint (TMJ)

For Medicare plans only, we'll no longer require precertification for the following:

Effective July 15, 2025, we'll require

precertification for the following:

Hyperbaric oxygen therapy (HBOT)

Encelto[™] (revakinagene taroretcel-

lwey, J3490, J3590, C9399)

Submitting precertification requests

Submit precertification requests at least two weeks in advance and include the actual date of service in the request. To save time, request precertification online through our provider portal on Availity.*

Doing so is fast, secure and simple.

Electronic Medical Record (EMR) system if it's set up for electronic precertification requests. Use our "Search by CPT® code"

If you need precertification for a specialty

drug for a commercial or Medicare

member, submit your request through Novologix®, also available on Availity.

*Availity® is available only to providers in

the U.S. and its territories.

function on our Precertification Lists page to find out if the code requires

precertification.**

You can also use your practice's

care (SOC))

J3590, C9399)

This month's

July 2025

Subject:

Learn about important policy Trouble viewing this email message? Read it online

**CPT® is a registered trademark of the American Medical Association. 2024 All rights reserved. Note to Maine and Vermont providers: For commercial plans, your effective date for routine changes described in this article will be the statutory date of January 1, April 1, July 1 or October 1,

whichever date follows the effective

required by state or federal law, or pursuant to revisions of Current

statutory dates outlined above.

Site-of-care prior

authorization timeline

oncology drugs begin on

On October 1, 2025, we're updating our

timeline for certain oncology medications

site. These changes will affect only those

have an initial approval of 90 days when a

administered in an outpatient hospital

patients who are new to therapy after October 1. Certain oncology drugs will

place of service is outpatient hospital.

The affected oncology drugs are the

following Immune Checkpoint Inhibitors:

initial prior authorization approval

changes for certain

October 1

Affected drugs

 Bavencio Imfinzi

 Jemperli Keytruda Libtavo Loqtorzi Opdivo

Opdivo Qvantig

Tecentriq Hybreza

approvals, not existing ones.

You can access the Site of Care for

the medications to which this policy

site of care policy page.

Specialty Drug Administration policy and

applies on our **Drug infusion/injection**

You can always find this information on our provider

portal on Availity.*

You can also use our Code Edit

handy to access them.

Lookup tools on Availity®. Just go to Payer Space > Applications > Code Edit Lookup Tools. Keep your Aetna provider ID number

Availity portal

*Availity® is available only to providers in the

American Medical Association. 2024 All rights

Aetna® is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates

All registered company names, products and services are the property of their respective

Help/contact us: If you have any questions,

Want to stop receiving email messages like

We are located at 151 Farmington Avenue,

Privacy Statement | Terms of Use | Privacy

these? **Unsubscribe** at any time.

**CPT® is a registered trademark of the

U.S. and its territories.

reserved.

(Aetna).

owners.

please <u>contact us</u>.

Hartford, CT 06156.

<u>Information</u>

©2025 Aetna Inc. 5384116-01-01

Note that this change will affect only new

 Opdualag Tecentriq

 Tevimbra Unloxcyt Yervov Zynyz

More information

Procedural Terminology (CPT®) codes published by the American Medical

Association, may be effective outside the

date(s) referred to in this article. Changes